Best Life Sciences Platforms and Tools Companies in Seattle, United States
The 52 best Life Sciences Platforms and Tools companies in Seattle, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Avalyn Pharma.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Seattle
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Avalyn Pharma Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis 57Funding top 14%Growth top 30%News top 30%Moat top 31% All 7 signals ▾Fundingtop 14% Growthtop 30% Newstop 30% Moattop 31% Techtop 40% Globalbottom 39% Marketbottom 36% Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $289M | 12 mo ago | 24 | 2011 | — | WordPressApple iCloud MailMySQL+25 | — | — |
| 2 | Corus Pharma Developer of therapeutics for severe respiratory diseases | $144M | 243 mo ago | — | 2001 | Bruce Montgomery CEO | — | — | — |
| 3 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 14 mo ago | 54 54 → 61 (+13%) | 2009 | Joseph Victor President & CEO | — | 266 patents High-throughput multiplexed fluorescence microscopy and spectral imaging hardware | 1 launch |
| 4 | NanoString Developer of spatial biology tools for life sciences research | $108M | 76 mo ago | 652 | 2003 | Dwayne Dunaway Co-Founder & Director | WordPress Block EditorWordPressApple iCloud Mail+25 | 340 patents Spatial genomics and multiplexed single-cell analysis technologies for molecular profiling | — |
| 5 | Magnolia Medical Integrated system to reduce blood culture sample contamination | $104M | 47 mo ago | 77 77 → 81 (+5%) | 2006 | — | WordPressApple iCloud MailMicrosoft 365+21 | 433 patents Medical fluid handling devices for sampling, control, and contamination‑free delivery | — |
| 6 | Nautilus Biotechnology Developer of proteomics platform for drug development | $103M | 59 mo ago | 134 134 → 148 (+10%) | 2016 | Sujal Patel Co-Founder & CEO | WordPressMySQLPHP+24 | 90 patents Multiplexed single‑molecule protein analysis using nano‑ and micro‑array platforms | 2 launchs |
| 7 | Parse Biosciences Developer of RNA-sequencing solution-based transcriptome kit to analyze health data | $100M | 31 mo ago | 107 | 2018 | Geoff Krummel Co-Founder | WordPress Block EditorWordPressSentry+33 | — | 1 job opening · 1 launch |
| 8 | Arzeda Developer of enzyme design technology to bridge the gap by creating synthetic enzymes 80Funding top 20%Patents top 21%Innovation top 26%Growth top 28% All 11 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 26% Growthtop 28% Moattop 28% Talenttop 28% Producttop 40% Markettop 45% Partnerstop 45% Globalbottom 42% Newsbottom 18% Funding: Raised $90.7M across 22 rounds · 22 rounds over 17 yrs (1.3/yr) Patents: 85 patents matched (strict assignee match) · 52 filings since 2022 vs 21 in 2017-21 rank vs industry peers · Fliar Intelligence Index 80/100 | $91M | 11 mo ago | 60 60 → 78 (+30%) | 2008 | David Baker Co-Founder | — | 85 patents Enzymatic synthesis and modification of steviol glycoside sweeteners | — |
| 9 | Stratos Genomics Nanopore-based single molecule sequencer | $63M | 102 mo ago | 64 | 2007 | — | — | 142 patents High‑accuracy polymerases and nanopore sequencing methods for advanced DNA analysis | — |
| 10 | A-Alpha Bio Developer of cell-based tool for the measurements of protein interactions | $45M | 26 mo ago | 39 39 → 49 (+26%) | 2017 | Randolph Lopez Co-founder & CTO | Apple iCloud MailMicrosoft 365React+11 | — | 1 award |
| 11 | Presage Biosciences Translational oncology company pioneering drug development with its CIVO platform | $35M | 64 mo ago | 17 | 2008 | — | — | 90 patents Oncology combination drugs and low-profile multi-agent injection delivery systems | — |
| 12 | Healionics Manufacturer of synthetic biomaterials and implantable medical devices 27Talent top 15%Moat top 25%Funding top 35%Patents top 42% All 9 signals ▾Talenttop 15% Moattop 25% Fundingtop 35% Patentstop 42% Innovationbottom 47% Globalbottom 40% Techbottom 32% Marketbottom 20% Newsbottom 18% Talent: Analyst team rating 5/5 Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $27M | 7 mo ago | 10 | 2007 | — | WordPressMySQLPHP+15 | 42 patents Improving vascular graft patency and injectable porous ocular drug‑delivery devices. | — |
| 13 | Monod Developer of biosensors to detect viral proteins, toxins, antibodies, and other molecules | $25M | 30 mo ago | 27 | 2021 | Alfredo Rubio Co-Founder | — | — | — |
| 14 | Virtici Transforms innovations into life-changing medical products through leadership, space, and funding 11Funding top 42%Global bottom 35%Patents bottom 29%Innovation bottom 19% All 4 signals ▾Fundingtop 42% Globalbottom 35% Patentsbottom 29% Innovationbottom 19% Funding: Raised $24.2M across 27 rounds · 27 rounds over 14 yrs (1.9/yr) Global: Single-market focus (United States) rank vs industry peers · Fliar Intelligence Index 11/100 | $24M | 11 mo ago | 9 | 2011 | — | — | 7 patents Inducing immune tolerance to peptide antigens for allergy and autoimmune therapies | — |
| 15 | PAI Life Sciences Translational research for neglected diseases, vaccines, adjuvants, and protein biotherapeutics | $24M | 15 mo ago | 5 | 2004 | — | — | — | — |
| 16 | Amnis Cell analysis solutions advancing cancer and cell biology research | $15M | 204 mo ago | 30 | 1998 | — | — | 100 patents High-throughput imaging flow cytometry for cellular and circulating tumor cell analysis | — |
| 17 | AVM Biotech Small molecule and biologics for regenerative medicine, oncology, and fully human biologics | $13M | 47 mo ago | 15 | 2008 | — | WordPressMySQLPHP+14 | — | — |
| 18 | Synthesize Bio Provider of AI-generated gene expression data for biological research purposes | $10M | 10 mo ago | — | 2023 | Robert Bradley Co-Founder | WebflowApple iCloud MailGSAP+13 | — | 1 launch |
| 19 | Acylin Therapeutics Identified small molecule inhibitor of histone acetyl transferase | $6M | 169 mo ago | — | 2009 | Suresh Jain Co-founder | — | — | — |
| 20 | Phase Genomics Provider of laboratory and computational services and products | $6M | 15 mo ago | 19 19 → 14 (-26%) | 2015 | — | — | 22 patents High-throughput sequencing-based genome analysis and bacterial lysin therapeutics. | — |
| 21 | Neoleukin Therapeutics Manufacturers of therapeutic proteins to treat immunological disorders | $5M | 185 mo ago | 7 | 2003 | Jonathan Drachman CEO & President | — | — | — |
| 22 | PETX Optimizing breast cancer therapy with advanced imaging technology | $5M | 17 mo ago | 5 | 2012 | Paul E. Kinahan Co-Founder | — | — | — |
| 23 | Nexgenia Smart immunoassay polymer reagents improving speed, efficiency, and sensitivity for diagnostics | $4M | 98 mo ago | 2 | 2011 | Ron Myers CEO | — | 10 patents Stimuli-responsive polymers for cell-surface targeting and magnetic nanoparticle biosensing | — |
| 24 | Stemgenics Provider of stem cell technology that converts mature skin cells into stem cells | $3M | 97 mo ago | 5 | 2008 | Andranik Andrew Aprikyan EVP | — | 50 patents Nanoparticle-based intracellular delivery of gene editing and cell reprogramming agents | — |
| 25 | Deverra Therapeutics Provider of progenitor blood and immune cells for clinical application | $2M | 34 mo ago | 13 | 2020 | Colleen Delaney Founder | — | — | — |
| 26 | MarqMetrix Manufacturer of Raman spectroscopic instruments | $1M | 106 mo ago | 30 | 2012 | — | — | 51 patents Compact Raman spectroscopy and fluidic optical cells for analytical instrumentation | — |
| 27 | ID Genomics Diagnostics for drug resistant infections. | $736K | 59 mo ago | 3 | 2012 | — | — | 149 patents Blood-based cardiovascular diagnostics and automated tissue sample processing technologies. | — |
| 28 | Truly Tech Developer of bioprocessing solutions for biomolecule isolation | $328K | 38 mo ago | — | 2021 | Dave M Managing Director | — | — | — |
| 29 | Universal Cells Engineering allogeneic stem cells for universal cell therapy treatments | $300K | 138 mo ago | 26 | 2013 | — | Craft CMSBugHerdPHP+6 | — | — |
| 30 | Plurexa Developer of cell models for human disease | $298K | 39 mo ago | — | 2022 | Benjamin Freedman Founder & Chief Executive Officer | — | — | — |
| 31 | Silene Biotech Offers biobanking services | $120K | 97 mo ago | 6 | 2014 | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Seattle
#1
Public · Seattle, Washington · founded 2011 · 24 employees$288.9Mraised▾
Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis. The company's lead program, Aerodone inhaled pirfenidone provides GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. FDA has granted orphan-drug designation to Genoa for the use of pirfenidone.
- Jul 2025Series D$100M
- Sep 2023Series C$189.2M
- Apr 2020Series B$35.5M
- 2017Series A—
#2
Series B · Seattle, Washington · founded 2008 · 60 employees$90.7Mraised▾
Developer of enzyme design technology to bridge the gap by creating synthetic enzymes. The proprietary technology combines targeted computational enzyme design and protein optimization with metabolic bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production.
- Aug 2025Series B$4.5M
- May 2025Grant (prize money)$1.7M
- Apr 2025Grant (prize money)$2.2M
- Oct 2023Series B$38M
#3
Series C · Seattle, Washington · founded 2007 · 10 employees$26.6Mraised▾
Healionics is a manufacturer of synthetic biomaterials and implantable medical devices. It provides tissue regeneration and device bio integration solutions to medical device manufacturers. It offers sphere-templated angiogenic regeneration (STAR) technology, which provides substrate independent, precision-engineered, and 3D biomaterial scaffolds that enhance the bio-integration and promote healing of implanted medical devices. The company’s products are used in various areas, including wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, and urological/women's health.
- Dec 2025Series C$2M
- Apr 2024Grant (prize money)$953.4K
- Oct 2023Series C$5.5M
- May 2021Series C$5.5M
#4
Series C · Seattle, Washington · founded 2009 · 54 employees$114.3Mraised▾
Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging and analysis).
- May 2025Grant (prize money)$658.3K
- Jun 2024Series C$20M
- Jul 2023Series C$13.2M
- Sep 2021Series C$24M
#5
Funding Raised · Seattle, Washington · founded 2011 · 9 employees$24.2Mraised▾
Transforms innovations into life-changing medical products through leadership, space, and funding. The company focuses on transforming scientific innovations into valuable medical products, addressing significant health challenges. It operates with an ecosystem of universities, businesses, and investment groups, fostering innovation and cost-efficient product development. The company actively seeks innovative product and platform concepts in areas like oncology, microbiome, longevity, autoimmunity, inflammation, and infectious diseases. It provides leadership and funding support to advance novel treatments and therapies. The company is a life science innovation and product development company.
- Aug 2025Grant (prize money)$309K
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$602.8K
- Apr 2025Grant (prize money)$2.7M
#6
Funding Raised · Seattle, Washington · founded 2004 · 5 employees$23.6Mraised▾
Translational research for neglected diseases, vaccines, adjuvants, and protein biotherapeutics. The company specializes in developmental and translational research, bridging the gap from laboratory discoveries to clinical applications. They focus on addressing overlooked global health challenges through innovative solutions. Their expertise lies in developing protein-based antigens and therapeutics, with a pipeline encompassing infectious disease vaccines, adjuvants, and cancer therapeutics. They offer services in vaccine and diagnostic discovery, process development, and product prototyping. The company utilizes molecular, immunological, and chemical research, with fully-equipped lab facilities. Their approach includes bioinformatics and wet lab capabilities to advance partnered projects and antigenic leads. They aim to create a social impact by serving underserved populations through scientific advancements.
- Apr 2025Grant (prize money)$5.5M
- 2024Grant (prize money)$295.4K
- 2023Grant (prize money)$300K
- 2021Grant (prize money)$243K
#7
Series A · Seattle, Washington · founded 2023$10Mraised▾
Provider of AI-generated gene expression data for biological research purposes. The company offers a platform enabling scientists to generate and analyze genomic data. It allows users to customize AI models, combine AI and experimental data, and visualize expression data. The platform supports molecular experiment design, synthetic control generation, and rare sample augmentation. It also facilitates data analysis, collaboration, and access to preprocessed public data.
- Sep 2025Series A$10M
#8
Series A · Seattle, Washington · founded 2015 · 19 employees$5.8Mraised▾
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics' Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
- Apr 2025Grant (prize money)$299.2K
- Jan 2025Grant (prize money)$2M
- Mar 2024Grant (prize money)$1.5M
- Sep 2023Grant (prize money)$2M
#9
Funding Raised · Seattle, Washington · founded 2012 · 5 employees$4.7Mraised▾
Optimizing breast cancer therapy with advanced imaging technology. They combine positron emission tomography and X-ray mammography to determine effective targeted therapies for breast cancer patients, avoiding delays and side effects. Their solution is valuable for testing new treatments in clinical trials. They are a research-focused organization developing innovative medical instruments. This is a B2B tech company focused on healthcare, specifically oncology. Their technology has a significant social impact by improving cancer treatment outcomes. They are developing a medical device for research use.
- Feb 2025Grant (prize money)$2M
- Jul 2017Grant (prize money)$359.9K
- Sep 2016Grant (prize money)$2M
- Aug 2013Grant (prize money)$406.6K
#10
Series C · Seattle, Washington · founded 2018 · 107 employees$100.3Mraised▾
Developer of RNA-sequencing solution-based transcriptome kit to analyze health data. It offers solutions that empower researchers to run fixed samples collected on different dates together in a single experiment by providing control over sample handling and reducing errors. The kit uses barcoding to label single cells or single-nucleus suspension for sequencing as well as the tools for data analysis.
- Dec 2023Venture Debt—
- Dec 2023Series C$50M
- Feb 2022Series B$41.5M
- Jan 2021Series A$7M
#11
Series A · Seattle, Washington · founded 2017 · 39 employees$45.2Mraised▾
Developer of cell-based tool for the measurements of protein interactions. The company offers cell-based platform technology that measures protein interactions with the help of engineered yeast cells. It enhances drug development by measuring protein interactions.
- May 2024Grant (prize money)$14.5M
- Jul 2023Series A$22.4M
- May 2023Grant (prize money)$2.4M
- Sep 2021Series A$20M
#12
Series C · Seattle, Washington · founded 2006 · 77 employees$104.1Mraised▾
Magnolia Medical Technologies, is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed the SteriPath system including a blood collection system, sterile package and sample collection procedure aimed at minimizing sample contamination. SteriPath is a vacuum-assisted blood collection system that diverts and sequesters contaminants from the initial blood sample specimen and reduces blood culture sample contaminations. According to Magnolia’s website, SteriPath comes in 3 different configurations and is compatible with standard blood collection tubes and culture bottles made by Becton Dickinson and bioMerieux.
- Jul 2022Series C$100K
- Jan 2022Series C$46M
- May 2020Venture Debt$20M
- Jan 2019Series C$20M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Seattle researches in bioinformatics
- Seattle Children\'s Hospital11
- Seattle University9
- Seattle Reproductive Medicine2
- Seattle Cancer Care Alliance2
- Seattle Public Schools1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.